Please use this identifier to cite or link to this item:
|Title:||Dengue vaccines : dawning at last?||Authors:||Wilder-Smith, Annelies||Keywords:||DRNTU::Science::Medicine||Issue Date:||2014||Source:||Wilder-Smith, A. (2014). Dengue vaccines : dawning at last? The Lancet, 384(9951), 1327-1329.||Series/Report no.:||The Lancet||Abstract:||The need for a dengue vaccine is more pressing than ever. Dengue—a mosquito-borne viral infection caused by any of the four dengue virus serotypes—is regarded as the most important arboviral disease globally, because more than 50% of the world's population live in regions at risk of the disease, and evidence points towards further geographical and numerical expansion.1 The results of Maria Capeding and colleagues' multicentre phase 3, randomised, observer-masked, placebo-controlled efficacy trial2 for a recombinant, chimeric, live attenuated tetravalent dengue vaccine (CYD-TDV), in The Lancet, have been awaited with great anticipation paired with some trepidation, on the basis of the disappointing results from a previous single-centre trial with the same vaccine in Thailand.||URI:||https://hdl.handle.net/10356/103775
|ISSN:||0140-6736||DOI:||http://dx.doi.org/10.1016/S0140-6736(14)61142-9||Rights:||© 2014 Elsevier. This is the author created version of a work that has been peer reviewed and accepted for publication by The Lacet, Elsevier. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/S0140-6736(14)61142-9].||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.